Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy

    July 2025 in “ Allergy ”
    Xi Li, Elena Peeva, Yuji Yamaguchi … Emma Guttman‐Yassky
    Studysummary In this study, ritlecitinib treatment for 12 and 24 weeks downregulated immunity-related genes and upregulated hair keratin genes in patients with alopecia areata, correlating with scalp hair regrowth response.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 30

    1. Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme Journal of the European Academy of Dermatology and Venereology · 2025
    2. Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata British Journal of Dermatology · 2024
    3. Hair Regrowth in Alopecia Areata and Re-Pigmentation in Vitiligo in Response to Treatment: Commonalities and Differences Journal of the European Academy of Dermatology and Venereology · 2024
    4. Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences International journal of molecular sciences · 2024
    5. Interleukin-15 Is a Hair Follicle Immune Privilege Guardian Journal of Autoimmunity · 2024
    6. The Alopecia Areata Severity And Morbidity Index (ASAMI) Study JAMA Dermatology · 2024
    7. Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions Frontiers in immunology · 2023
    8. Janus Kinase Inhibitors for Alopecia Areata Journal of the American Academy of Dermatology · 2023
    9. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    10. Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs Clinical, Cosmetic and Investigational Dermatology · 2023
    11. Keratin-Mediated Hair Growth and Its Underlying Biological Mechanism Communications biology · 2022
    12. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    13. The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications Cells · 2021
    14. Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2021
    15. Role of Scalp Health in Achieving Optimal Hair Growth and Retention International Journal of Cosmetic Science · 2021
    16. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    17. Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata International Journal of Molecular Sciences · 2021
    18. The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside Frontiers in immunology · 2020
    19. Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata Experimental dermatology · 2020
    20. Alopecia Areata Is Characterized by Dysregulation in Systemic Type 17 and Type 2 Cytokines, Which May Contribute to Disease-Associated Psychological Morbidity British journal of dermatology/British journal of dermatology, Supplement · 2019
    21. Systemic Treatments for Alopecia Areata: A Systematic Review Australasian journal of dermatology · 2018
    22. An Integrated Model of Alopecia Areata Biomarkers Highlights Both TH1 and TH2 Upregulation Journal of Allergy and Clinical Immunology · 2018
    23. Altered Expression of Intracellular Toll-Like Receptors in Peripheral Blood Mononuclear Cells from Patients with Alopecia Areata BBA clinical · 2016
    24. Biomarkers of Alopecia Areata Disease Activity and Response to Corticosteroid Treatment Experimental dermatology · 2015
    25. Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism The Journal of Allergy and Clinical Immunology · 2015
    26. Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2015
    27. The Autoimmune Basis of Alopecia Areata: A Comprehensive Review Autoimmunity reviews · 2014
    28. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    29. Alopecia Areata: An Autoimmune Disease Causing Hair Loss The New England Journal of Medicine · 2012
    30. Alopecia Areata Update Journal of the American Academy of Dermatology · 2010

    Related research 4

    1. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    2. Linear Alopecia Areata JAAD case reports · 2018
    3. Treating Resistant Cases of Alopecia Universalis Journal of cosmetology & trichology · 2018
    4. Overview of Alopecia Areata ˜The œjournal of investigative dermatology. Symposium proceedings/˜The œJournal of investigative dermatology symposium proceedings · 2013